Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A New Pain PILL: Lending a Personal Approach to Personalized Medicine

David S. Pisetsky, MD, PhD  |  Issue: November 2010  |  November 1, 2010

As a scientist, I gravitate toward numbers, especially quantifiable outcome measures, and am a great fan of questionnaires that patients can easily complete. The numbers generated are illuminating, often surprising, and can as readily bolster our clinical impression as refute them. Pennybaker’s index is such a measure. It is therefore with hope and anticipation that I await the day when rheumatologists routinely use this measure in practice and, harkening back to a bygone era, instruct their patients, “Please take this PILL. If you still hurt, please call me in the morning.”

Dr. Pisetsky is physician editor of The Rheumatologist and professor of medicine and immunology at Duke University Medical Center in Durham, N.C.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res. 62: 590–599.

Page: 1 2 3 | Single Page
Share: 

Filed under:Drug UpdatesOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnostic CriteriaPainPennybaker Index of Limbic LanguidnessPILLQuality

Related Articles

    Revising Fibromyalgia: One Year Later

    July 12, 2011

    The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care

    Is Fibromyalgia Overdiagnosed?

    October 10, 2016

    Are too many patients diagnosed with fibromyalgia? The co-authors of one new study believe that close to 75% of patients who have received a clinical fibromyalgia diagnosis do not meet the 2010 Preliminary American College of Rheumatology (ACR) Criteria for Fibromyalgia.1 They say these patients are false-positive and may be taking treatments they don’t need….

    Diagnosing & Caring for Patients with Fibromyalgia

    May 19, 2022

    Doebl et al. compared the effect of symptoms and the healthcare use of people with fibromyalgia with those who fulfilled the criteria for fibromyalgia but had not been diagnosed and those with chronic pain. They found patients diagnosed with fibromyalgia reported the poorest healthcare experiences and were more likely than other study participants to be unemployed due to health issues. Their findings reveal an urgent need exists for a model of care for patients with fibromyalgia.

    Treat-to-Target Strategy Evaluated for Fibromyalgia Care

    September 19, 2017

    Treat-to-target is a widely used approach for rheumatoid arthritis, in which rheumatologists prescribe treatments to reach established benchmarks of disease activity.1 Is it time for a similar approach for fibro­myalgia treatment, even though its pathogenesis, disease-activity measures and treatment algorithms are less well understood? Three fibromyalgia researchers present their case in a new paper, “Treat-to-Target…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences